ABBOTT LABORATORIES

ABT 10-Q · Q1 2026
API behind this page

ABT Q1 2026 request

Playground key active
Request URL /api/financials?ticker=ABT&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 11,164 10,358 +7.8%
Show Business Segments breakouts
Diagnostic Products · Cancer Diagnostics 96 — —
Diagnostic Products · Core Laboratory 1,272 1,177 +8.1%
Diagnostic Products · Non Us 1,275 1,183 +7.8%
Diagnostic Products · Non Us 925 845 +9.5%
Diagnostic Products · Non Us 347 338 +2.7%
Diagnostic Products · Non Us 3 — —
Diagnostic Products · Operating Segments 2,180 2,054 +6.1%
Diagnostic Products · Rapid and Molecular 812 877 -7.4%
Diagnostic Products · US 905 871 +3.9%
Diagnostic Products · US 347 332 +4.5%
Diagnostic Products · US 465 539 -13.7%
Diagnostic Products · US 93 — —
Established Pharmaceuticals · Key Emerging Markets 1,089 965 +12.8%
Established Pharmaceuticals · Non Us 1,426 1,260 +13.2%
Established Pharmaceuticals · Non Us 1,089 965 +12.8%
Established Pharmaceuticals · Non Us 337 295 +14.2%
Established Pharmaceuticals · Operating Segments 1,426 1,260 +13.2%
Established Pharmaceuticals · Other 337 295 +14.2%
Medical Devices · Diabetes Care 2,080 1,827 +13.8%
Medical Devices · Electrophysiology 788 675 +16.7%
Medical Devices · Heart Failure 389 339 +14.7%
Medical Devices · Neuromodulation 243 228 +6.6%
Medical Devices · Non Us 3,016 2,556 +18.0%
Medical Devices · Non Us 1,258 1,079 +16.6%
Medical Devices · Non Us 410 342 +19.9%
Medical Devices · Non Us 97 77 +26.0%
Medical Devices · Non Us 66 52 +26.9%
Medical Devices · Non Us 345 281 +22.8%
Medical Devices · Non Us 354 283 +25.1%
Medical Devices · Non Us 486 442 +10.0%
Medical Devices · Operating Segments 5,539 4,895 +13.2%
Medical Devices · Rhythm Management 684 585 +16.9%
Medical Devices · Structural Heart 578 531 +8.9%
Medical Devices · US 2,523 2,339 +7.9%
Medical Devices · US 822 748 +9.9%
Medical Devices · US 378 333 +13.5%
Medical Devices · US 292 262 +11.5%
Medical Devices · US 177 176 +0.6%
Medical Devices · US 339 304 +11.5%
Medical Devices · US 224 248 -9.7%
Medical Devices · US 291 268 +8.6%
Medical Devices · Vascular 777 710 +9.4%
Nutritional Products · Adult Nutritionals 1,064 1,105 -3.7%
Nutritional Products · Non Us 1,173 1,191 -1.5%
Nutritional Products · Non Us 731 738 -0.9%
Nutritional Products · Non Us 442 453 -2.4%
Nutritional Products · Operating Segments 2,017 2,146 -6.0%
Nutritional Products · Pediatric Nutritionals 953 1,041 -8.5%
Nutritional Products · US 844 955 -11.6%
Nutritional Products · US 333 367 -9.3%
Nutritional Products · US 511 588 -13.1%
Show Geography breakouts
Non Us 6,890 6,190 +11.3%
US 4,274 4,168 +2.5%
US · Corporate Non Segment 2 3 -33.3%
Show Consolidation Items breakouts
Corporate Non Segment 2 3 -33.3%
Operating Segments 11,162 10,355 +7.8%
Cost of Revenue 4,890 4,468 +9.4%
Show Business Segments breakouts
Diagnostic Products · Operating Segments 1,242 1,152 +7.8%
Established Pharmaceuticals · Operating Segments 644 569 +13.2%
Medical Devices · Operating Segments 1,814 1,598 +13.5%
Nutritional Products · Operating Segments 1,089 1,124 -3.1%
Show Consolidation Items breakouts
Operating Segments 4,789 4,443 +7.8%
Total Costs & Expenses 9,819 8,665 +13.3%
Research & Development 767 716 +7.1%
Show Business Segments breakouts
Diagnostic Products · Operating Segments 155 151 +2.6%
Established Pharmaceuticals · Operating Segments 41 42 -2.4%
Medical Devices · Operating Segments 444 401 +10.7%
Nutritional Products · Operating Segments 54 52 +3.8%
Show Consolidation Items breakouts
Operating Segments 694 646 +7.4%
Selling, General & Administrative 3,740 3,061 +22.2%
Show Business Segments breakouts
Diagnostic Products · Operating Segments 448 392 +14.3%
Established Pharmaceuticals · Operating Segments 376 351 +7.1%
Medical Devices · Operating Segments 1,388 1,287 +7.8%
Nutritional Products · Operating Segments 563 576 -2.3%
Show Consolidation Items breakouts
Operating Segments 2,775 2,606 +6.5%
Operating Income 1,345 1,693 -20.6%
Show Business Segments breakouts
Diagnostic Products · Operating Segments 335 359 -6.7%
Established Pharmaceuticals · Operating Segments 365 298 +22.5%
Medical Devices · Operating Segments 1,893 1,609 +17.7%
Nutritional Products · Operating Segments 311 394 -21.1%
Show Consolidation Items breakouts
Operating Segments 2,904 2,660 +9.2%
Interest Expense 174 131 +32.8%
Interest Income -106 -82 -29.3%
Other Non-Operating Income (Expense) -159 -127 -25.2%
Income Before Taxes 1,449 1,778 -18.5%
Income Tax Expense (Benefit) 372 453 -17.9%
Net Income 1,077 1,325 -18.7%
Show Equity Components breakouts
Retained Earnings 1,077 1,325 -18.7%
Comprehensive Income 766 1,814 -57.8%
Other Comprehensive Income -311 489 -163.6%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -311 489 -163.6%
EPS (Basic) 0.62 0.76 -18.4%
EPS (Diluted) 0.61 0.76 -19.7%
Wtd Avg Shares (Basic) 1,742,480 1,739,206 +0.2%
Wtd Avg Shares (Diluted) 1,747,073 1,747,220 -0.0%
Foreign Currency Transaction Gain Loss Before Tax -13 -7 -85.7%
Net Income Loss Available To Common Stockholders Basic 1.1 1.3 -15.4%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 6,803 6,532 +4.1%
Short-Term Investments 492 312 +57.7%
Accounts Receivable 8,210 7,327 +12.1%
Inventory 6,989 6,639 +5.3%
Total Current Assets 25,508 23,153 +10.2%
Non-Current Assets
Property, Plant & Equipment 12,377 10,932 +13.2%
Goodwill 35,221 — —
Show Business Segments breakouts
Diagnostic Products 14.9 — —
Established Pharmaceuticals 2.7 — —
Medical Devices 17.3 — —
Nutritional Products 0.3 — —
Total Assets 110,429 — —
Show Business Segments breakouts
Diagnostic Products · Operating Segments 9,631 — —
Established Pharmaceuticals · Operating Segments 3,665 — —
Medical Devices · Operating Segments 10,983 — —
Nutritional Products · Operating Segments 4,903 — —
Show Consolidation Items breakouts
Operating Segments 29,182 — —
Long Term Investments 1,090 907 +20.2%
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure · Equity Securities 727 572 +27.1%
Carrying Reported Amount Fair Value Disclosure · Other Aggregated Investments 363 335 +8.4%
Estimate Of Fair Value Fair Value Disclosure · Equity Securities 727 572 +27.1%
Estimate Of Fair Value Fair Value Disclosure · Other Aggregated Investments 363 335 +8.4%
Show Investment Type breakouts
Equity Securities 727 572 +27.1%
Other Investments 363 335 +8.4%
Current Liabilities
Current Portion of Long-Term Debt 4,409 506 +771.3%
Total Current Liabilities 18,377 13,004 +41.3%
Non-Current Liabilities
Long-Term Debt 29,638 12,736 +132.7%
Long-Term Debt (Q) — — —
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure -34,047 -13,242 -157.1%
Estimate Of Fair Value Fair Value Disclosure -33,329 -12,975 -156.9%
Stockholders' Equity
Common Stock 25,352 25,125 +0.9%
Retained Earnings 49,956 47,715 +4.7%
Accumulated Other Comprehensive Income -6,312 -7,417 +14.9%
Total Stockholders' Equity 52,061 — —
Total Liabilities & Equity 110,429 81,448 +35.6%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Stock-Based Compensation 317 289 +9.7%
Change in Accounts Receivable -42 -262 +84.0%
Change in Inventory -420 -255 -64.7%
Net Cash from Operations 1,315 1,417 -7.2%
Investing Activities
Capital Expenditures -399 -484 +17.6%
Other Investing Activities 34 6 +466.7%
Net Cash from Investing -20,324 -470 -4224.3%
Financing Activities
Share Repurchases -180 -280 +35.7%
Net Cash from Financing 17,313 -2,055 +942.5%
Other Cash Flow
Net Change in Cash -1,719 -1,084 -58.6%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key